A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM)

被引：4

作者：

Ades, Lionel ^{[1
]}

Guerci-Bresler, Agnes ^{[2
]}

Cony-Makhoul, Pascale ^{[3
]}

Legros, Laurence ^{[4
]}

Sebert, Marie ^{[4
]}

Braun, Thorsten ^{[5
]}

Delaunay, Jacques ^{[6
]}

Desseaux, Kristell ^{[7
]}

Chevret, Sylvie ^{[7
]}

Fenaux, Pierre ^{[1
]}

机构：

[1] Univ Paris 07, St Louis Hosp, Serv Hematol Seniors, Paris, France

[2] Hop Adultes Brabois, Hematol Dept, Nancy, France

[3] Ctr Hosp Annecy, Metz, France

[4] CH Archet, Hematol Dept, Nice, France

[5] CHU Avicenne, Hematol Clin, Bobigny, France

[6] Nantes Univ Hosp, Dept Hematol, Nantes, France

[7] Univ Paris 07, Hop St Louis, Dept Stat DBIM, Paris, France

来源：

HAEMATOLOGICA | 2019年 / 104卷 / 04期

关键词：

ACUTE MYELOID-LEUKEMIA; AZACITIDINE;

D O I：

10.3324/haematol.2018.203885

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E131 / E133

页数：3

共 50 条

[1] A Phase II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (AZA) in Intermediate-2 and High Risk MDS Patients: A Study By the Groupe Francophone Des Myelodysplasies (GFM)
Ades, Lionel
Guerci-Bresler, Agnes
Cony-Makhoul, Pascale
Legros, Laurence
Sebert, Marie
Braun, Thorsten
Delaunay, Jacques
Samey, Benedicte
Desseaux, Kristell
Chevret, Sylvie
Fenaux, Pierre
[J]. BLOOD, 2015, 126 (23)
[2] A Phase II Study Of The Efficacy and Safety Of A Intensified Schedule Of Azacitidine (AZA) In Intermediate-2 and High Risk MDS Patients
Ades, Lionel
Guerci-Bresler, Agnes
Makhoul, Pascale Cony
Legros, Laurence
Delaunay, Jacques
Recher, Christian
Desseaux, Kristell
Samey, Benedicte
Chevret, Sylvie
Fenaux, Pierre
[J]. BLOOD, 2013, 122 (21)
[3] Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myelodysplasies (GFM)
Cluzeau, Thomas
Sebert, Marie
Rahme, Ramy
Cuzzubbo, Stefania
Lehmann-Che, Jacqueline
Madelaine, Isabelle
Peterlin, Pierre
Beve, Blandine
Attalah, Habiba
Chermat, Fatiha
Miekoutima, Elsa
Rauzy, Odile Beyne
Recher, Christian
Stamatoullas, Aspasia
Willems, Lise
Raffoux, Emmanuel
Berthon, Celine
Quesnel, Bruno
Loschi, Michael
Carpentier, Antoine F.
Sallman, David A.
Komrokji, Rami
Walter-Petrich, Anouk
Chevret, Sylvie
Ades, Lionel
Fenaux, Pierre
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (14) : 1575 - +
[4] SINGLE NUCLEOTIDE POLYMORPHISM ARRAY (SNP-A) KARYOTYPING IN LOWER RISK MYELODYSPLASTIC SYNDROMES (MDS), A STUDY BY THE GROUPE FRANCOPHONE DES MYELODYSPLASIES (GFM)
Ben Abdelali, R.
Gardin, C.
Geoffroy, S.
Nibourel, O.
Peyrouze, P.
Helvaut, N.
Thepot, S.
Rauzy, O. Beyne
Prebet, T.
Vey, N.
Dreyfus, F.
Fenaux, P.
Cheok, M.
Preudhomme, C.
[J]. HAEMATOLOGICA, 2012, 97 : 133 - 133
[5] A PHASE II STUDY OF THE EFFICACY AND SAFETY OF AN INTENSIFIED SCHEDULE OF AZACITIDINE IN HIGHER RISK MDS PATIENTS: A STUDY BY THE GFM
Ades, L.
Guerci-Bresler, A.
Makhoul, P. Cony
Legros, L.
Delaunay, J.
Recher, C.
Sebert, M.
Lejeune, J.
Chevret, S.
Fenaux, P.
[J]. LEUKEMIA RESEARCH, 2015, 39 : S44 - S44
[6] Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study
Ades, Lionel
Boehrer, Simone
Prebet, Thomas
Beyne-Rauzy, Odile
Legros, Laurence
Ravoet, Christophe
Dreyfus, Francois
Stamatoullas, Aspasia
Chaury, Marie Pierre
Delaunay, Jacques
Laurent, Guy
Vey, Norbert
Burcheri, Sara
Mbida, Rose-Marie
Hoarau, Natacha
Gardin, Claude
Fenaux, Pierre
[J]. BLOOD, 2009, 113 (17) : 3947 - 3952
[7] Azacitidine (AZA) Combined with Idarubicin in Higher Risk MDS - Results of a Phase I/II Study By the Groupe Francophone Des Myelodysplasies (GFM)
Sebert, Marie
Stamatoullas, Aspasia
Braun, Thorsten
Delaunay, Jacques
de Renzis, Benoit
Jeddi, Ramzi
Meddeb, Balkis
Berger, Mathilde Hunault
Samey, Benedicte
Chermat, Fatiha
Chevret, Sylvie
Chaffaut, Cendrine
Fenaux, Pierre
Ades, Lionel
[J]. BLOOD, 2015, 126 (23)
[8] Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM
Natarajan-Ame, Shanti
Park, Sophie
Ades, Lionel
Vey, Norbert
Guerci-Bresler, Agnes
Cahn, Jean-Yves
Etienne, Gabriel
Bordessoule, Dominique
Ravoet, Christophe
Legros, Laurence
Cheze, Stephane
Stamatoullas, Aspasia
Berger, Elisabeth
Schmidt, Aline
Charbonnier, Aude
Chaury, Marie-Pierre
Braun, Thorsten
Fenaux, Pierre
Dreyfus, Francois
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (02) : 232 - 237
[9] Red Blood Cell Transfusion Burden in Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS): A Retrospective Multicenter Study By the Groupe Francophone Des Myelodysplasies (GFM)
Jouzier, Claire
Cherait, Amina
Cony-Makhoul, Pascale
Thepot, Sylvain
Cluzeau, Thomas
Bastard, Aspasia Stamatoulas
Peterlin, Pierre
Bresler, Agnes Guerci
Dimicoli-Salazar, Sophie
Pica, Gian-Matteo
Cheze, Stephane
Santana, Clemence
Chermat, Fatiha
Fenaux, Pierre
Park, Sophie
[J]. BLOOD, 2020, 136
[10] Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myelodysplasies (GFM)
Jouzier, Claire
Cherait, Amina
Cony-Makhoul, Pascale
Hamel, Jean-Francois
Veloso, Melanie
Thepot, Sylvain
Cluzeau, Thomas
Stamatoullas, Aspasia
Garnier, Alice
Guerci-Bresler, Agnes
Dimicoli-Salazar, Sophie
Pica, Gian Matteo
Cheze, Stephane
Santana, Clemence
Chermat, Fatiha
Fenaux, Pierre
Park, Sophie
[J]. TRANSFUSION, 2022, 62 (05) : 961 - 973

← 1 2 3 4 5 →